Gregory B. Tallman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gregory B. Tallman has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Jessina C. McGregor
Department of Pharmacy Practice, College of Pharmacy, Oregon State University, Portland, OR, USA
3 shared publications Alex J. Adams
1 shared publicationAna F. Bienvenida
Department of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, Oregon, USA
1 shared publicationBo R. Weber
Department of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, Oregon, USA
1 shared publicationBrian Kendall
Providence Portland Medical Center
1 shared publication- Brie N. Noble
Department of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, Oregon, USA
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e238
Clinical outcomes of carbapenem vs. non-carbapenem therapy in hospitalized adults with shigellosis
Background: Management of shigellosis is increasingly complicated by antimicrobial resistance, yet susceptibility testing is rarely performed, and the role of broad-spectrum empiric therapy in hospitalized adults remains unclear. Methods: We conducted a multi-center retrospective cohort study of adults hospitalized with stool-confirmed Shigella spp. from October 2023 to August 2024 across five hospitals in the Portland metropolitan area. The primary outcome was time from antibiotic initiation to symptom resolution (less than 3 stools in 24 h) and the secondary outcome was length of hospital stay. Results: Of 45 patients included in the outcome analyses, 29 (64%) received carbapenems and 16 (36%) received non-carbapenem antibiotics. Median time from antibiotic initiation to symptom resolution was 18 hours (IQR 9–37) in the carbapenem group and 29 hours (IQR 15–36) in the non-carbapenem group, with no significant difference between groups ( P = .89). The median length of hospital stay was significantly longer in the carbapenem group, at 5.4 days (IQR 3.6–8.3), compared with 3.9 days (IQR 2.6–4.4) in the non-carbapenem group ( P = .02). Only 26% of patients had susceptibility testing ordered. Conclusions: Carbapenem use was not associated with faster symptom resolution and was associated with significantly longer hospitalization. Susceptibility testing was underutilized and may be essential to guide local empiric and targeted therapy decisions.
- 10 August 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e238
Open AccessClinical outcomes of carbapenem vs. non-carbapenem therapy in hospitalized adults with shigellosis
Background: Management of shigellosis is increasingly complicated by antimicrobial resistance, yet susceptibility testing is rarely performed, and the role of broad-spectrum empiric therapy in hospitalized adults remains unclear. Methods: We conducted a multi-center retrospective cohort study of adults hospitalized with stool-confirmed Shigella spp. from October 2023 to August 2024 across five hospitals in the Portland metropolitan area. The primary outcome was time from antibiotic initiation to symptom resolution (less than 3 stools in 24 h) and the secondary outcome was length of hospital stay. Results: Of 45 patients included in the outcome analyses, 29 (64%) received carbapenems and 16 (36%) received non-carbapenem antibiotics. Median time from antibiotic initiation to symptom resolution was 18 hours (IQR 9–37) in the carbapenem group and 29 hours (IQR 15–36) in the non-carbapenem group, with no significant difference between groups ( P = .89). The median length of hospital stay was significantly longer in the carbapenem group, at 5.4 days (IQR 3.6–8.3), compared with 3.9 days (IQR 2.6–4.4) in the non-carbapenem group ( P = .02). Only 26% of patients had susceptibility testing ordered. Conclusions: Carbapenem use was not associated with faster symptom resolution and was associated with significantly longer hospitalization. Susceptibility testing was underutilized and may be essential to guide local empiric and targeted therapy decisions.
- Open Access
- 29 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 672
General Perceptions and Knowledge of Antibiotic Resistance and Antibiotic Use Behavior: A Cross-Sectional Survey of US Adults
This study aimed to assess understanding of antibiotic resistance and evaluate antibiotic use themes among the general public. In March 2018, respondents that were ≥21 years old and residing in the United States were recruited from ResearchMatch.org and surveyed to collect data on respondent expectations, knowledge, and opinions regarding prescribing antibiotics and antibiotic resistance. Content analysis was used to code open-ended definitions of antibiotic resistance into central themes. Chi-square tests were used to assess differences between the definitions of antibiotic resistance and antibiotic use. Among the 657 respondents, nearly all (99%) had taken an antibiotic previously. When asked to define antibiotic resistance, the definitions provided were inductively coded into six central themes: 35% bacteria adaptation, 22% misuse/overuse, 22% resistant bacteria, 10% antibiotic ineffectiveness, 7% body immunity, and 3% provided an incorrect definition with no consistent theme. Themes that were identified in respondent definitions of resistance significantly differed between those who reported having shared an antibiotic versus those who had not (p = 0.03). Public health campaigns remain a central component in the fight to combat antibiotic resistance. Future campaigns should address the public’s understanding of antibiotic resistance and modifiable behaviors that may contribute to resistance.
- 29 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 672
Open AccessGeneral Perceptions and Knowledge of Antibiotic Resistance and Antibiotic Use Behavior: A Cross-Sectional Survey of US Adults
This study aimed to assess understanding of antibiotic resistance and evaluate antibiotic use themes among the general public. In March 2018, respondents that were ≥21 years old and residing in the United States were recruited from ResearchMatch.org and surveyed to collect data on respondent expectations, knowledge, and opinions regarding prescribing antibiotics and antibiotic resistance. Content analysis was used to code open-ended definitions of antibiotic resistance into central themes. Chi-square tests were used to assess differences between the definitions of antibiotic resistance and antibiotic use. Among the 657 respondents, nearly all (99%) had taken an antibiotic previously. When asked to define antibiotic resistance, the definitions provided were inductively coded into six central themes: 35% bacteria adaptation, 22% misuse/overuse, 22% resistant bacteria, 10% antibiotic ineffectiveness, 7% body immunity, and 3% provided an incorrect definition with no consistent theme. Themes that were identified in respondent definitions of resistance significantly differed between those who reported having shared an antibiotic versus those who had not (p = 0.03). Public health campaigns remain a central component in the fight to combat antibiotic resistance. Future campaigns should address the public’s understanding of antibiotic resistance and modifiable behaviors that may contribute to resistance.
- 16 September 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (6) , 751-752
Comment: Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting
- 16 September 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (6) , 751-752
Comment: Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting
Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre
Summary: Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high‐risk immunocompromised patients.Patients/Methods: Retrospective, single‐centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period.Results: One hundred thirty‐eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug‐related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001).Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high‐risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost‐effectiveness of isavuconazole in this role.
Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre
Summary: Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high‐risk immunocompromised patients.Patients/Methods: Retrospective, single‐centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period.Results: One hundred thirty‐eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug‐related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001).Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high‐risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost‐effectiveness of isavuconazole in this role.
- Open Access
- 1 October 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (10)
Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole.
- 1 October 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (10)
Open AccessClinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole.
- 26 September 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (12) , 2045-2052
Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients
In Pseudomonas aeruginosa, fluoroquinolone exposure promotes resistance to carbapenems through up-regulation of efflux pumps and transcriptional down-regulation of the porin OprD. Evidence of this effect among hematologic malignancy (HM) patients or hematopoietic-cell transplant (HCT) recipients receiving fluoroquinolone prophylaxis for neutropenia is lacking. We retrospectively evaluated episodes of P. aeruginosa bloodstream infections in HM patients or HCT recipients over a 7-year period at our institution. The association of fluoroquinolone prophylaxis at the time of infection with meropenem susceptibility of P. aeruginosa breakthrough isolates and risk factors for meropenem non-susceptibility were determined. Whole genome sequencing (WGS) and phenotypic assessment of meropenem efflux pump activity were performed on select isolates to determine the mechanisms of meropenem resistance. Fifty-five episodes of P. aeruginosa bacteremia among 51 patients were analyzed. Breakthrough bacteremia while on fluoroquinolone prophylaxis was associated with non-susceptibility to meropenem but not to anti-pseudomonal β-lactams or aminoglycosides. Receipt of fluoroquinolone prophylaxis was independently predictive of bacteremia with a meropenem non-susceptible isolate. All meropenem non-susceptible isolates analyzed by WGS contained oprD inactivating mutations, and all meropenem non-susceptible isolates tested demonstrated reduction in the meropenem MIC in the presence of an efflux pump inhibitor. Phylogenetic analysis based on WGS revealed several clusters of closely related isolates from different patients. Fluoroquinolone prophylaxis in HM patients and HCT recipients is associated with breakthrough bacteremia with meropenem non-susceptible P. aeruginosa strains, likely due to both mutations increasing efflux pump activity and the epidemiology of P. aeruginosa bloodstream infections in our patient population.
- 26 September 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (12) , 2045-2052
Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients
In Pseudomonas aeruginosa, fluoroquinolone exposure promotes resistance to carbapenems through up-regulation of efflux pumps and transcriptional down-regulation of the porin OprD. Evidence of this effect among hematologic malignancy (HM) patients or hematopoietic-cell transplant (HCT) recipients receiving fluoroquinolone prophylaxis for neutropenia is lacking. We retrospectively evaluated episodes of P. aeruginosa bloodstream infections in HM patients or HCT recipients over a 7-year period at our institution. The association of fluoroquinolone prophylaxis at the time of infection with meropenem susceptibility of P. aeruginosa breakthrough isolates and risk factors for meropenem non-susceptibility were determined. Whole genome sequencing (WGS) and phenotypic assessment of meropenem efflux pump activity were performed on select isolates to determine the mechanisms of meropenem resistance. Fifty-five episodes of P. aeruginosa bacteremia among 51 patients were analyzed. Breakthrough bacteremia while on fluoroquinolone prophylaxis was associated with non-susceptibility to meropenem but not to anti-pseudomonal β-lactams or aminoglycosides. Receipt of fluoroquinolone prophylaxis was independently predictive of bacteremia with a meropenem non-susceptible isolate. All meropenem non-susceptible isolates analyzed by WGS contained oprD inactivating mutations, and all meropenem non-susceptible isolates tested demonstrated reduction in the meropenem MIC in the presence of an efflux pump inhibitor. Phylogenetic analysis based on WGS revealed several clusters of closely related isolates from different patients. Fluoroquinolone prophylaxis in HM patients and HCT recipients is associated with breakthrough bacteremia with meropenem non-susceptible P. aeruginosa strains, likely due to both mutations increasing efflux pump activity and the epidemiology of P. aeruginosa bloodstream infections in our patient population.
- 1 March 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (5) , 578-583
Empiric Antibiotic Prescribing Decisions Among Medical Residents: The Role of the Antibiogram
OBJECTIVE: To assess general medical residents’ familiarity with antibiograms using a self-administered surveyDESIGN: Cross-sectional, single-center surveyPARTICIPANTS: Residents in internal medicine, family medicine, and pediatrics at an academic medical centerMETHODS: Participants were administered an anonymous survey at our institution during regularly scheduled educational conferences between January and May 2012. Questions collected data regarding demographics, professional training; further open-ended questions assessed knowledge and use of antibiograms regarding possible pathogens, antibiotic regimens, and prescribing resources for 2 clinical vignettes; a series of directed, closed-ended questions followed. Bivariate analyses to compare responses between residency programs were performed.RESULTS: Of 122 surveys distributed, 106 residents (87%) responded; internal medicine residents accounted for 69% of responses. More than 20% of residents could not accurately identify pathogens to target with empiric therapy or select therapy with an appropriate spectrum of activity in response to the clinical vignettes; correct identification of potential pathogens was not associated with selecting appropriate therapy. Only 12% of respondents identified antibiograms as a resource when prescribing empiric antibiotic therapy for scenarios in the vignettes, with most selecting the UpToDate online clinical decision support resource or The Sanford Guide. When directly questioned, 89% reported awareness of institutional antibiograms, but only 70% felt comfortable using them and only 44% knew how to access them.CONCLUSIONS: When selecting empiric antibiotics, many residents are not comfortable using antibiograms as part of treatment decisions. Efforts to improve antibiotic use may benefit from residents being given additional education on both infectious diseases pharmacotherapy and antibiogram utilization.Infect Control Hosp Epidemiol 2018;39:578–583
- 1 March 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (5) , 578-583
Empiric Antibiotic Prescribing Decisions Among Medical Residents: The Role of the Antibiogram
OBJECTIVE: To assess general medical residents’ familiarity with antibiograms using a self-administered surveyDESIGN: Cross-sectional, single-center surveyPARTICIPANTS: Residents in internal medicine, family medicine, and pediatrics at an academic medical centerMETHODS: Participants were administered an anonymous survey at our institution during regularly scheduled educational conferences between January and May 2012. Questions collected data regarding demographics, professional training; further open-ended questions assessed knowledge and use of antibiograms regarding possible pathogens, antibiotic regimens, and prescribing resources for 2 clinical vignettes; a series of directed, closed-ended questions followed. Bivariate analyses to compare responses between residency programs were performed.RESULTS: Of 122 surveys distributed, 106 residents (87%) responded; internal medicine residents accounted for 69% of responses. More than 20% of residents could not accurately identify pathogens to target with empiric therapy or select therapy with an appropriate spectrum of activity in response to the clinical vignettes; correct identification of potential pathogens was not associated with selecting appropriate therapy. Only 12% of respondents identified antibiograms as a resource when prescribing empiric antibiotic therapy for scenarios in the vignettes, with most selecting the UpToDate online clinical decision support resource or The Sanford Guide. When directly questioned, 89% reported awareness of institutional antibiograms, but only 70% felt comfortable using them and only 44% knew how to access them.CONCLUSIONS: When selecting empiric antibiotics, many residents are not comfortable using antibiograms as part of treatment decisions. Efforts to improve antibiotic use may benefit from residents being given additional education on both infectious diseases pharmacotherapy and antibiogram utilization.Infect Control Hosp Epidemiol 2018;39:578–583
- 1 November 2017
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 23 (6) , 593-600
Potential for Pharmacy–Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases
Context: Health care professionals must continually identify collaborative ways to combat antibiotic resistance while improving community health and health care delivery. Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived point-of-care (POC) testing (POCT) services for infectious disease conducted in community pharmacies provide a means for pharmacists to collaborate with prescribers and/or public health officials combating antibiotic resistance while improving community health and health care delivery. Objective: To provide a comprehensive literature review that explores the potential for pharmacists to collaborate with public health professionals and prescribers using pharmacy-based CLIA-waived POCT services for infectious diseases. Design: Comprehensive literature review. Setting: PubMed and Google Scholar were searched for manuscripts and meeting abstracts for the following key words: infectious disease, community pharmacy, rapid diagnostic tests, rapid assay, and POC tests. Intervention: All relevant manuscripts and meeting abstracts utilizing POCT in community pharmacies for infectious disease were reviewed. Outcome Measure: Information regarding the most contemporary evidence regarding CLIA-waived POC infectious diseases tests for infectious diseases and their use in community pharmacies was synthesized to highlight and identify opportunities to develop future collaborations using community pharmacy-based models for such services. Results: Evidence demonstrates that pharmacists in collaboration with other health care professionals can leverage their knowledge and accessibility to provide CLIA-waived POCT services for infectious diseases. Testing for influenza may augment health departments' surveillance efforts, help promote rationale antiviral use, and avoid unnecessary antimicrobial therapy. Services for human immunodeficiency virus infection raise infection status awareness, increase access to health care, and facilitate linkage to appropriate care. Testing for group A streptococcal pharyngitis may curb inappropriate outpatient antibiotic prescribing. However, variance in pharmacy practice statues and the application of CLIA across states stifle collaboration. Conclusion: CLIA-waived POCT services for infectious diseases are a means for pharmacists, public health professionals, and prescribers to collaboratively combat antibiotic resistance and improve community health.
- 1 November 2017
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 23 (6) , 593-600
Potential for Pharmacy–Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases
Context: Health care professionals must continually identify collaborative ways to combat antibiotic resistance while improving community health and health care delivery. Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived point-of-care (POC) testing (POCT) services for infectious disease conducted in community pharmacies provide a means for pharmacists to collaborate with prescribers and/or public health officials combating antibiotic resistance while improving community health and health care delivery. Objective: To provide a comprehensive literature review that explores the potential for pharmacists to collaborate with public health professionals and prescribers using pharmacy-based CLIA-waived POCT services for infectious diseases. Design: Comprehensive literature review. Setting: PubMed and Google Scholar were searched for manuscripts and meeting abstracts for the following key words: infectious disease, community pharmacy, rapid diagnostic tests, rapid assay, and POC tests. Intervention: All relevant manuscripts and meeting abstracts utilizing POCT in community pharmacies for infectious disease were reviewed. Outcome Measure: Information regarding the most contemporary evidence regarding CLIA-waived POC infectious diseases tests for infectious diseases and their use in community pharmacies was synthesized to highlight and identify opportunities to develop future collaborations using community pharmacy-based models for such services. Results: Evidence demonstrates that pharmacists in collaboration with other health care professionals can leverage their knowledge and accessibility to provide CLIA-waived POCT services for infectious diseases. Testing for influenza may augment health departments' surveillance efforts, help promote rationale antiviral use, and avoid unnecessary antimicrobial therapy. Services for human immunodeficiency virus infection raise infection status awareness, increase access to health care, and facilitate linkage to appropriate care. Testing for group A streptococcal pharyngitis may curb inappropriate outpatient antibiotic prescribing. However, variance in pharmacy practice statues and the application of CLIA across states stifle collaboration. Conclusion: CLIA-waived POCT services for infectious diseases are a means for pharmacists, public health professionals, and prescribers to collaboratively combat antibiotic resistance and improve community health.